← Back to Search

Omega-3 Fatty Acid

Docosa Hexanoic Acid for Autism Spectrum Disorder

N/A

Waitlist Available

Led By Sherie Novotny, MD

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up three years

Awards & highlights

Study Summary

This trialtests if DHA, a component of fish oil, can help reduce symptoms of autism in children and adolescents.

Who is the study for?

This trial is for children and adolescents aged 5-17 with Autism Spectrum Disorder. Participants must meet specific autism diagnostic criteria, be seizure-free for at least 6 months if applicable, and capable of giving consent through a guardian. Sexually active females must use birth control. Those with certain medical conditions or on recent psychoactive medications are excluded.Check my eligibility

What is being tested?

The study tests the effects of Docosahexanoic Acid (DHA), an omega-3 fatty acid found in fish oil, against a placebo over 12 weeks to see if it improves symptoms of autism. It also examines genetic factors related to DHA and its biomarkers in urine.See study design

What are the potential side effects?

While not explicitly listed in the provided information, potential side effects may include typical reactions associated with omega-3 supplements such as fishy aftertaste, gastrointestinal discomfort or disturbances, and allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ three years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~three years

This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Amelioration of phenotypic features of autism

Secondary outcome measures

oxidative stress biomarkers

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Docosa Hexanoic AcidActive Control1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

64,100 Total Patients Enrolled

10 Trials studying Autism Spectrum Disorder

177 Patients Enrolled for Autism Spectrum Disorder

Sherie Novotny, MDPrincipal InvestigatorRutgers-RWJMS

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an opportunity for me to sign up for this experiment?

"This clinical trial is enrolling 132 children and adolescents between the ages of 5-17 who have been diagnosed with autism. To meet eligibility, they must not be using any anticonvulsant medication but still haven't had a seizure in 6 months or longer; alternatively, those taking anticonvulsants must also have gone at least 6 months without seizures. Furthermore, patients enrolled in this study may display abnormal EEG readings even if there are no extant signs of seizures. All participants will remain as outpatients throughout the duration of their involvement."

Answered by AI

Are there any opportunities currently available to partake in this experiment?

"Per the information hosted on clinicaltrials.gov, this experiment has ceased recruitment of participants; although it was initially posted in November 2010 and last updated October 25th 2022, its participant intake is currently inactive. Fortunately, there are 199 other trials that do have open enrollment at present."

Answered by AI

Is geriatric recruitment being accepted for this research study?

"The specifications for this trial dictate that only those aged between 5 to 17 are eligible. According to the data, there are 169 research opportunities available for minors and 33 medical studies targeting seniors over 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

Sherie Novotny, M.D. 2010. "Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01260961.

All > Uti